author-photo

Dragana Bugarski-Kirola

ACADIA Pharmaceuticals Inc.

4

Papers

3

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Comorbidities and behavioral issues.

2021 European Neuropsychopharmacology
- Dragana Bugarski-Kirola
- Ronald N. Marcus
Show All
- Source
- Cite
- Save
Citations (1)
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.

2021 The Lancet Psychiatry
Show All
- Source
- Cite
- Save
Citations (0)
T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT

2020 Schizophrenia Bulletin
Show All
- Source
- Cite
- Save
Citations (1)
T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT

2020 Schizophrenia Bulletin
Show All
- Source
- Cite
- Save
Citations (1)